Immune checkpoint blockade and CAR T-cell therapy in T-cell/histiocyte-rich large B-cell lymphoma: Challenges and opportunities
Open Access
- 18 September 2024
- Vol. 10 (18) , e38023
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapyBlood, 2022
- Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy in T-cell/histiocyte-rich large B-cell lymphomaBlood, 2021
- Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphomaBlood, 2021
- CD19-specific CAR T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor are Effective in Patients with PD-L1–positive B-Cell LymphomaClinical Cancer Research, 2020
- High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphomaBlood Advances, 2020
- Diffuse large B-cell lymphoma variants: an updatePathology, 2020
- Clinical features and survival of patients with T-cell/histiocyte-rich large B-cell lymphoma: analysis of the National Cancer Data BaseLeukemia & Lymphoma, 2019
- Targeting the Immune Microenvironment in Lymphomas of B-Cell Origin: From Biology to Clinical ApplicationCancers, 2019
- PD-1 blockade modulates chimeric antigen receptor (CAR)–modified T cells: refueling the CARBlood, 2017
- T-Cell/Histiocyte-Rich Large B-Cell Lymphomas and Classical Diffuse Large B-Cell Lymphomas Have Similar Outcome After Chemotherapy: A Matched-Control AnalysisJournal of Clinical Oncology, 2003